16 September 2026 editorial review · Trial
SCD0503 oral insulin clamp vs subcutaneous human insulin: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: No additional discrepancy identified in the reviewed summary/design/endpoint and eligibility fields. Existing sponsor or historical claims are not all independently certified by this protocol comparison.
Registry: NCT07634770. Endpoint reviewed: AUCins.0-6h, area under the serum insulin concentration curve from 0 to 6 hours (From enrollment to the end of treatment in 4 months); Cins.max, maximum observed insulin concentration (From enrollment to the end of treatment in 4 months); AUCGIR.0-6h, area under the insulin concentration-time curve from 0 to 6 hours (From enrollment to the end of treatment in 4 months); GRELcl, Relative biopotency (will be derived of the dose corrected ratio of AUCGIR.0-6h for oral and sc insulin) (From enrollment to the end of treatment in 4 months). Eligibility reviewed: Age 18 Years to 64 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.